

| Name | Company | Characteristics | Approved Uses | FDA Aprv |
|---|--|--|--|--------------------------------|
| Hyaluronic Acid (HA) Fillers | | | | |
| BELOTERO Balance® (+) | Merz | Bacteria-based HA filler, cross-linked with BDDE, containing 0.3% lidocaine. Total HA concentraion: 22.5 mg/mL | For injection into the mid to deep dermis for the correction of moderate to severe facial wrinkles and folds (such as nasolabial folds). For improvement of the infraorbital hollow (IOH) in adults over the age of 21. | Nov-2011 Sep-2023 |
| SKINVIVE™ by Juvéderm® | Allergan Aesthetics, an AbbVie Company | Bacteria-based HA Filler, cross-linked with BDDE, containing 0.3% lidocaine. Total HA concentration: 12.5 g/mL | For intradermal injection to improve skin smoothness of the cheeks in adults over the age of 21. | May - 2023 |
| Juvéderm® Ultra XC Juvéderm® Ultra Plus XC | Allergan Aesthetics, an AbbVie Company | Bacteria-based HA filler, cross-linked with BDDE, containing 0.3% lidocaine. Total HA concentration: 24 mg/mL | For deep (subcutaneous and/or supraperiosteal) injection for cheek augmentation to correct age-related mid-face volume deficit in adults over the age of 21. For injection into the mid-to-deep dermis for correction of moderate to severe wrinkles and folds (such as nasolabial folds). Ultra XC is also indicated for injection into the lips and perioral area for lip augmentation in adults over the age of 21. | Jun-2006 |
| Juvéderm® Volbella® XC | Allergan Aesthetics, an AbbVie Company | Bacteria-based HA filler, cross-linked with BDDE, containing 0.3% lidocaine. Total HA concentration: 15 mg/mL | For deep (subcutaneous and/or supraperiosteal) injection for cheek augmentation to correct age-related mid-face volume deficit in adults over the age of 21. For use in the lips for lip augmentation and for correction of perioral rhytids, commonly referred to as perioral lines, in adults over the age of 21. For the improvement of infraorbital hollowing in adults over the age of 21. | Jun-2016 Feb-2022 |
| Juvéderm® Vollure® XC | Allergan Aesthetics, an AbbVie Company | Bacteria-based HA filler, cross-linked with BDDE, containing 0.3% lidocaine. Total HA concentration: 17.5 mg/mL | For deep (subcutaneous and/or supraperiosteal) injection for cheek augmentation to correct age-related volume deficit in the mid-face in adults over 21. For the correction of moderate to severe facial wrinkles and folds, such as nasolabial folds in adults over the age of 21. | Mar-2017 |
| Juvéderm® Voluma® XC | Allergan Aesthetics, an AbbVie Company | Bacteria-based HA filler, cross-linked with BDDE, containing 0.3% lidocaine. Total HA concentration: 20 mg/mL | For deep (subcutaneous and/or supraperiosteal) injection for cheek augmentation to correct age-related volume deficit in the mid-face in adults over 21. Approved for mid-face injection via a STERIGLIDE™ cannula (9/2019). Also approved for augmentation of the chin region to improve the chin profile in adults over the age of 21 (6/2020). | Oct-2013 |
| Juvéderm® Volux™ XC | Allergan Aesthetics, an AbbVie Company | Bacteria-based HA filler, cross-linked with BDDE, containing 0.3% lidocaine. Total HA concentration: 25 mg/mL | For subcutaneous and/or supraperiosteal injection for improvement in jawline definition in adults over the age of 21. | Aug-2022 |
| Restylane®/Restylane®- L | Galderma | Bacteria-based HA filler, cross-linked with BDDE. Total HA concentration: 20 mg/mL. Particle size range: 330-430 µm. Restylane-L contains 0.3% lidocaine | For injection into the mid to deep dermis for the correction of moderate to severe facial wrinkles and folds (such as the nasolabial folds). Also indicated for submucosal implantation for lip augmentation in patients over the age of 21. | Dec-2003 Oct-2011 (Lip aug) |
| Restylane® Contour | Galderma | Bacteria-based HA filler, cross-linked with BDDE, containing 0.3% lidocaine. Total HA concentration: 20.0 mg/mL | For use in cheek augmentation and for the correction of midface contour deficiencies in adults over the age of 21. | Jun-2021 |
| Restylane® Defyne | Galderma | Bacteria-based HA filler, cross-linked with BDDE, containing 0.3% lidocaine. Total HA concentration: 20.0 mg/mL | For injection into the mid-to-deep dermis for correction of moderate to severe, deep facial wrinkles and folds (such as nasolabial folds) in patients over the age of 21. Also approved for the augmentation and correction of mild to moderate chin retrusion in adults over the age of 21 (2/2021). | Dec-2016 |

| Name | Company | Characteristics | Approved Uses | FDA Aprv |
|-------------------------------------|----------------------------|---|--|------------------------------------|
| Hyaluronic Acid (HA) Fillers | | | | |
| Restylane® Eyelight | Galderma | Bacteria-based HA filler, cross-linked with BDDE, containing 0.3% lidocaine. Total HA concentration: 20 mg/mL | For the treatment of undereye hollows, also know as dark shadows, in adults over the age of 21. | Jun-2023 |
| Restylane® Kysse | Galderma | Bacteria-based HA filler, cross linked with BDDE, containing 0.3% lidocaine. Total HA concentration: 20mg/mL. This product has a moderate lifting capacity | For injection into the lips for lip augmentation and the correction of upper perioral rhytids in patients over the age of 21. | May-2020 |
| Restylane® Lyft | Galderma | Bacteria-based HA filler, cross-linked with BDDE, containing lidocaine 0.3%. Total HA concentration: 20 mg/mL. Particle size range: 750-1000 µm | For implantation into the deep dermis to superficial subcutis for the correction of moderate to severe facial folds and wrinkles, such as nasolabial folds. For subcutaneous to surpapeiosteal implantation for cheek augmentation and correction of age-related midface contour deficiencies in patients over the age of 21. For injection into the subcutaneous plane in the dorsal hand to correct volume deficit in patients over the age of 21. | Feb-2010 May-2018 (Hand aug) |
| Restylane® Refyne | Galderma | Bacteria-based HA filler, cross-linked with BDDE, containing 0.3% lidocaine. Total HA concentration: 20.0 mg/mL; Restylane Refyne is less crosslinked than Restylane Defyne | For injection into the mid-to-deep dermis for correction of moderate to severe facial wrinkles and folds (such as nasolabial folds) in patients over the age of 21. | Dec-2016 |
| Restylane® Silk | Galderma | Bacteria-based HA filler, cross-linked with BDDE, containing 0.3% lidocaine. Total HA Concentration: 20 mg/mL; Particle size range: 50–220 µm | For submucosal implantation for lip augmentation and dermal implantation for correction of perioral rhytids in patients over the age of 21. | Jun-2014 |
| Revanesse® Lips | Prollenium US | Bacteria-based HA filler, cross-linked with BDDE, containing 0.3% lidocaine. Total HA concentration 22-28 mg/mL | For submucosal implantation for lip augmentation in patients 22 years of age or older. | Sept-2020 |
| Revanesse® Versa | Prollenium US | Bacteria-based HA filler, cross-linked with BDDE. Total HA concentration: 25 mg/mL | For injection into the mid to deep dermis for correction of moderate to severe facial wrinkles and folds, such as nasolabial folds in adults, 22 years of age or more. | Apr-2017 |
| RHA® 2 | Revence Therapeutics, Inc. | Bacteria-based HA filler, cross-linked with BDDE, containing 0.3% lidocaine. Total HA concentration: 23 mg/g. | For injection in the mid-to-deep dermis for the correction of moderate to severe dynamic facial wrinkles and folds, such as nasolabial folds (NLF) in adults aged 22 years or older. | Oct-2017 |
| RHA® 3 | Revence Therapeutics, Inc. | Bacteria-based HA filler, cross-linked with BDDE, containing 0.3% lidocaine. Total HA concentration: 23 mg/g. | For injection in the mid-to-deep dermis for the correction of moderate to severe dynamic facial wrinkles and folds, such as nasolabial folds (NLF) in adults aged 22 years or older. | Oct-2017 |
| RHA® 4 | Revence Therapeutics, Inc. | Bacteria-based HA filler, cross-linked with BDDE, containing 0.3% lidocaine. Total HA concentration: 23 mg/g. | For injection into the deep dermis to superficial subcutaneous tissue for the correction of moderate to severe dynamic facial wrinkles and folds, such as nasolabial folds (NLF) in adults aged 22 years or older. | Oct-2017 |
| RHA® Redensity | Revence Therapeutics, Inc. | Bacteria-based HA filler, cross-linked with BDDE, containing 0.3% lidocaine. Total HA concentration: 15 mg/mL | For injection into the dermis and superficial dermis of the face, for the correction of moderate to severe dynamic perioral rhytids, in adults aged 22 years or older. | Oct-2022 |

| Name | Company | Characteristics | Approved Uses | FDA Aprv |
|--------------------------------------|--|--|--|---|
| Biostimulatory Fillers | | | | |
| Radiesse® / Radiesse Plus® | Merz | Calcium hydroxylapatite (CaHA) microspheres suspended in an aqueous gel carrier. Radiesse Plus contains 0.3% lidocaine | For subdermal implantation for the correction of moderate to severe facial wrinkles and folds, such as nasolabial folds; also intended for restoration and/or correction of the signs of facial fat loss (lipoatrophy) in people with human immunodeficiency virus (HIV). For hand augmentation to correct volume loss in the dorsum of the hands. Indicated for deep injection (subdermal and/or supraperiosteal) for soft tissue augmentation to improve moderate to severe loss of jawline contour in adults over the age of 21. Deep injection (subdermal and/or supraperiosteal) for soft tissue augmentation to improve moderate to severe loss of jawline contour in adults over the age of 21. | Cosmetic indication: Dec-2006 Hand indication: Jun-2015 Jawline indication: Feb-2021 |
| Sculptra® Aesthetic | Galderma | Microparticles of poly-L-lactic acid (PLLA) - lyophilized product | Intended for restoration and/or correction of the signs of facial fat loss (lipoatrophy) in people with human immunodeficiency virus. Indicated for correction of shallow to deep nasolabial fold contour deficiencies and other facial wrinkles for use in immune-competent subjects. Indicated for correction of fine lines and wrinkles in the cheek region for use in immune competent subjects. | Aug-2004 Cosmetic indication: Jul-2009 Cheek wrinkle indication: Apr. 2023 |
| Permanent Fillers | | | | |
| Bellafill® | Suneva Medical | Polymethylmethacrylate microspheres (PMMA) suspended in 3.5% denatured bovine collagen, mixed with 0.3% lidocaine. Skin test required | For the correction of nasolabial folds and moderate to severe, atrophic, distensible facial acne scars on the cheeks of patients over the age of 21. | Oct-2006 |
| Neuromodulators | | | | |
| BOTOX® Cosmetic (onabotulinumtoxinA) | Allergan Aesthetics, an AbbVie Company | Purified protein produced by the <i>Clostridium botulinum</i> bacterium; onabotulinumtoxinA. Single use vial containing 50 or 100 units | For the temporary improvement in the appearance of moderate to severe glabellar lines associated with corrugator and/or procerus muscle activity in adult patients. For the temporary improvement in the appearance of moderate to severe lateral canthus lines associated with orbicularis oculi activity in adult patients. For moderate to severe forehead lines associated with frontalis activity. | Apr-2002 |
| Daxxify™ (daxibotulinumtoxinA-lanm) | Revance Therapeutics, Inc. | Derived from fermentation of <i>Clostridium botulinum</i> and available as a single use vial containing 50 or 100 units | For the temporary improvement in the appearance of moderate to severe glabellar lines associated with corrugator and/or procerus muscle activity in adult patients. | Sep-2022 |
| Dysport™ (abobotulinumtoxinA) | Galderma | Purified protein produced by the <i>Clostridium botulinum</i> bacterium; abobotulinumtoxinA. Single use vial containing 300 or 500 units | For the temporary improvement of moderate to severe glabellar lines associated with corrugator and/or procerus muscle activity in adult patients < 65 years of age. | Apr-2009 |
| Jeuveau™ (prabotulinumtoxinA-xvfs) | Evolus | Derived from fermentation of <i>Clostridium botulinum</i> and available as a single use vial containing 100 units | For the temporary improvement in the appearance of moderate to severe glabellar lines associated with corrugator and/or procerus muscle activity in adults. | Feb-2019 |
| Xeomin® (incobotulinumtoxinA) | Merz | Purified protein produced by the <i>Clostridium botulinum</i> bacterium; incobotulinumtoxinA. Single use vial containing 50 or 100 units | For the temporary improvement in the appearance of moderate to severe glabellar lines associated with corrugator and/or procerus muscle activity in adult patients. | Jul-2011 |